AR045004A1 - Composiciones farmaceuticas que comprenden 11-piperazin-1-ildibenzo[b,f][1,4]tiazepina - Google Patents

Composiciones farmaceuticas que comprenden 11-piperazin-1-ildibenzo[b,f][1,4]tiazepina

Info

Publication number
AR045004A1
AR045004A1 ARP040102345A ARP040102345A AR045004A1 AR 045004 A1 AR045004 A1 AR 045004A1 AR P040102345 A ARP040102345 A AR P040102345A AR P040102345 A ARP040102345 A AR P040102345A AR 045004 A1 AR045004 A1 AR 045004A1
Authority
AR
Argentina
Prior art keywords
disorders
pharmaceutically acceptable
bipolar
symptoms
tiazepina
Prior art date
Application number
ARP040102345A
Other languages
English (en)
Original Assignee
Schuckmann Alfred Von
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schuckmann Alfred Von filed Critical Schuckmann Alfred Von
Publication of AR045004A1 publication Critical patent/AR045004A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Abstract

Un método para el tratamiento de ansiedad, agitación, hostilidad, pánico, desórdenes de la alimentación, síntomas afectivos, síntomas emocionales, síntomas psicóticos positivos y negativos asociados comúnmente con esquizofrenia, demencia, ansiedad, depresión, trastornos emocionales, trastornos bipolares, manía bipolar, depresión bipolar, trastornos cognitivos y trastornos neurodegenerativos, que comprende administrar una cantidad eficaz de un compuesto de fórmula (1), o su sal farmacéuticamente aceptable. Composición farmacéutica que comprende una cantidad eficaz de un compuesto de fórmula (1) o su sal farmacéuticamente aceptable y por lo menos un diluyente o portador farmacéuticamente aceptable.
ARP040102345A 2003-07-02 2004-07-02 Composiciones farmaceuticas que comprenden 11-piperazin-1-ildibenzo[b,f][1,4]tiazepina AR045004A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48436503P 2003-07-02 2003-07-02

Publications (1)

Publication Number Publication Date
AR045004A1 true AR045004A1 (es) 2005-10-12

Family

ID=33563981

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102345A AR045004A1 (es) 2003-07-02 2004-07-02 Composiciones farmaceuticas que comprenden 11-piperazin-1-ildibenzo[b,f][1,4]tiazepina

Country Status (20)

Country Link
US (1) US20050026900A1 (es)
EP (1) EP1644005B1 (es)
JP (1) JP2007516193A (es)
KR (1) KR20060082037A (es)
CN (1) CN1816339B (es)
AR (1) AR045004A1 (es)
AT (1) ATE477803T1 (es)
AU (1) AU2004253334A1 (es)
BR (1) BRPI0412127A (es)
CA (1) CA2531284A1 (es)
DE (1) DE602004028739D1 (es)
ES (1) ES2349091T3 (es)
IL (1) IL172616A0 (es)
IS (1) IS8283A (es)
MX (1) MXPA05013869A (es)
NO (1) NO20060556L (es)
RU (1) RU2005141060A (es)
TW (1) TW200509944A (es)
UY (1) UY28400A1 (es)
WO (1) WO2005002586A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4414237B2 (ja) * 2002-03-20 2010-02-10 テバ ファーマシューティカル インダストリーズ リミティド ケチアピンヘミフマレートの結晶形
WO2008021463A2 (en) * 2006-08-15 2008-02-21 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20060081361A1 (en) * 2004-09-13 2006-04-20 Gabbey Lawrence W Oil cooler with integral filter
EP1838325A1 (en) * 2005-01-07 2007-10-03 AstraZeneca AB NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f][1,4]THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS
US20060252744A1 (en) * 2005-04-04 2006-11-09 Burstein Ethan S Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents
WO2006113425A1 (en) * 2005-04-14 2006-10-26 Teva Pharmaceutical Industries Ltd. Process for preparing quetiapine fumarate
WO2007004234A1 (en) * 2005-07-04 2007-01-11 Usv Limited A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE
CN101360502B (zh) * 2005-11-18 2012-03-14 阿斯利康公司 结晶形式
JP2009516705A (ja) * 2005-11-18 2009-04-23 アストラゼネカ・アクチエボラーグ 塩の形態
JP2009516708A (ja) * 2005-11-18 2009-04-23 アストラゼネカ・アクチエボラーグ 液体製剤
US20090215744A1 (en) * 2005-11-18 2009-08-27 Astrazeneca Ab Solid Formulations
US8389510B2 (en) 2005-11-18 2013-03-05 Astrazeneca Ab Crystalline forms
WO2008118141A2 (en) * 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
JP2010514682A (ja) * 2006-12-20 2010-05-06 アストラゼネカ・アクチエボラーグ 化合物及びその使用
EP2124908A4 (en) * 2006-12-20 2011-04-27 Astrazeneca Ab CONNECTIONS AND ITS USE
JP2010514684A (ja) * 2006-12-20 2010-05-06 アストラゼネカ・アクチエボラーグ 化合物及びその使用
JP2010522211A (ja) * 2007-03-22 2010-07-01 アストラゼネカ・アクチエボラーグ 気分障害を治療する方法
AU2010336981B2 (en) * 2009-12-31 2014-04-10 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
US20110223207A1 (en) 2010-03-11 2011-09-15 Travis Mickle Fatty Acid Conjugates of Quetiapine, Process for Making and Using the Same
CN102552128B (zh) * 2012-02-28 2013-09-18 陆荣政 一种富马酸喹硫平注射液及其制备方法
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL140242B (nl) * 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
GB1192812A (en) * 1966-05-20 1970-05-20 American Cyanamid Co 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3966949A (en) * 1973-10-12 1976-06-29 Richardson-Merrell Inc. Pharmaceutical compositions and preparing same
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US5750566A (en) * 1994-08-12 1998-05-12 Eli Lilly And Company Synthetic excitatory amino acids
AU5489299A (en) * 1998-08-18 2000-03-14 Sepracor, Inc. Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
MXPA05007784A (es) * 2003-01-23 2005-09-30 Acadia Pharm Inc Empleo de la n-desmetilclozapina para tratar las enfermedades neuropsiquiatricas humanas.

Also Published As

Publication number Publication date
CN1816339B (zh) 2010-12-15
JP2007516193A (ja) 2007-06-21
US20050026900A1 (en) 2005-02-03
CN1816339A (zh) 2006-08-09
WO2005002586A8 (en) 2006-02-09
DE602004028739D1 (de) 2010-09-30
ATE477803T1 (de) 2010-09-15
RU2005141060A (ru) 2006-07-27
AU2004253334A1 (en) 2005-01-13
IS8283A (is) 2006-02-01
ES2349091T3 (es) 2010-12-27
WO2005002586A1 (en) 2005-01-13
BRPI0412127A (pt) 2006-08-15
MXPA05013869A (es) 2006-02-28
IL172616A0 (en) 2006-04-10
EP1644005A1 (en) 2006-04-12
EP1644005B1 (en) 2010-08-18
UY28400A1 (es) 2005-01-31
CA2531284A1 (en) 2005-01-13
KR20060082037A (ko) 2006-07-14
TW200509944A (en) 2005-03-16
NO20060556L (no) 2006-04-03

Similar Documents

Publication Publication Date Title
AR045004A1 (es) Composiciones farmaceuticas que comprenden 11-piperazin-1-ildibenzo[b,f][1,4]tiazepina
GT200100183A (es) Derivados de quinolina y quinazolina.
PE20070541A1 (es) Compuestos y composiciones que comprenden isoindol-imidas
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
ATE540678T1 (de) Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen
CL2012000348A1 (es) Metodo para tratar o reducir la gravedad de la osteoporosis u osteopenia en un paciente que comprende administrarle el compuesto n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida o una sal del mismo; composicion farmaceutica.
BRPI0414082A (pt) formas de dosagem de liberação sustentada de ziprasidona
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
DE60239931D1 (de) Kombinationstherapie
TW200722100A (en) A therapeutic agent for a β related disorders
DE602004032522D1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
UY27993A1 (es) Derivados de 4-pirrolidino-fenil-bencil eter
BR0213355A (pt) composições farmacêuticas
GT199900154A (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
UY29924A1 (es) Medicamentos en base a 11-(4-(2-(2-hidroxietoxi)etil)-1-piperazinil)dibenzo-(b,f)(1,4)tiazepina y sus sales farmacéuticamente aceptables
BRPI0416534A (pt) composições multiparticuladas com estabilidade melhorada
UY27018A1 (es) Derivados de la pirimidina
BRPI0406824A (pt) Indolonaoxazoldinonas antiibacterianas, intermediários para seu preparo e composições farmacêuticas que as contêm
BRPI0410623A (pt) composto, processo para preparação de um composto, composição farmacêutica, e, utilização de um composto
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
EA200900269A1 (ru) Лекарственные комбинации для лечения заболеваний дыхательных путей
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
AR045005A1 (es) Composiciones farmaceuticas que comprenden 11-piperazin-1-ildibenzo[b,f][1,4]tiazepin-7-ol

Legal Events

Date Code Title Description
FA Abandonment or withdrawal